Double medicament controlled-release coating micropore ACS bracket

A dual-drug and coating technology, applied in the field of medical materials, can solve the problems of limited amount of applied drugs, short time, and inability to achieve therapeutic effects, and can inhibit smooth muscle proliferation, promote healing, and improve drug release rate and directionality. the effect of the control

Inactive Publication Date: 2008-06-18
天津市凯迪亚医疗器械有限公司
View PDF0 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, it has been proposed to prevent restenosis by coating drugs that prevent the proliferation of smooth muscle cells on coronary stents. Due to the single type of drugs coated on the surface of the ste

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Double medicament controlled-release coating micropore ACS bracket
  • Double medicament controlled-release coating micropore ACS bracket

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] The drug of the outer drug sustained-release coating of the coronary stent double-drug sustained-release coating adopts rapamycin (paclitaxel can also be used, the principle of action of the two is basically the same, and the present embodiment and the following embodiments use rapamycin prime as an example). The inner drug sustained-release coating is made of chloroform propionate, the outer drug sustained-release coating is made on the surface of the metal main component and connecting rod by ultrasonic atomization spraying process, and the inner drug sustained-release coating is filled in the serpentine In the multiple micropores on the section, the molar ratio n(dl-LA) / n(GA) of the polymer carrier polylactic acid-glycolic acid (PLGA) used is 80 / 20, the molecular weight is 200000, and the polymer The weight ratio of carrier to rapamycin and clobes propionate is 7:1.

[0024] The aforementioned rapamycin and clobes propionate are interchangeable.

Embodiment 2

[0026] In the coronary stent double-drug sustained-release coating, rapamycin is used for the drug sustained-release coating in the outer layer, pimecrolimus is used for the drug sustained-release coating in the inner layer, and direct coating is used for the drug sustained-release coating in the outer layer. The process is made on the surface of the metal main component and the connecting rod, and the inner layer of drug sustained-release coating is filled in multiple micropores on the serpentine section. The polymer carrier used is poly-n-butyl methacrylate (PBMA). The molar ratio n(dl-LA) / n(GA) is 90 / 10-50 / 50, and the molecular weight is 5000-400000. The weight ratio of the polymer carrier to rapamycin and pimecrolimus is 3:1.

[0027] The aforementioned rapamycin and pimecrolimus are interchangeable.

Embodiment 3

[0029] The drug sustained-release coating of the coronary stent double-drug sustained-release coating uses rapamycin as the drug in the outer layer of the sustained-release drug coating, ester glycol as the drug in the drug sustained-release coating in the inner layer, and an air spray process for the drug sustained-release coating in the outer layer. On the surface of the metal main body component and the connecting rod, the inner drug slow-release coating is filled in a plurality of micropores on the serpentine section, and the molar ratio of the polymer carrier polylactic acid-glycolic acid (PLGA) used is n (dl-LA) / n(GA) was 50 / 50, the molecular weight was 400,000, and the weight ratio of polymer carrier to rapamycin and ester diol was 10:1.

[0030] The rapamycin and ester diols mentioned above are interchangeable.

[0031] The technical principle of the present invention: the dual-drug slow-release coating of the coronary stent uses an innovative cobalt-chromium alloy or ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a millipore coronary stent with double-drug-slow-released coatings The coronary stent is structured by a plurality of metal main-structural members and connecting rods, wherein, the metal main-structural member is a regular snake-shaped ring which is formed by connecting an arc segment and a snake segment; neighboring main-structural members are connected by the connecting rod to form a ring support of a cylinder-wall; a plurality of millipores are opened on the snake-shaped segment; an outer drug-slow-released coating is coated on all metal main-structural members and connecting rods; an inner drug-slow-released coating is filled in the millipores on the snake-shaped segment of the metal-main-structural members. The double-drug-slow-released coatings of the coronary stent, through the slow-released function of the polymer coatings, can guarantee that different drugs can release at the given drug-releasing speeds, so as to guarantee that the drugs can adopts different releasing orders and durative acting times according to different pathogenesis.

Description

technical field [0001] The invention relates to a coronary stent in the field of medical materials, in particular to a microporous coronary stent with a double-drug slow-release coating. Background technique [0002] Percutaneous balloon intraluminal coronary angioplasty is a new treatment method for treating cardiovascular diseases in recent years. Coronary artery stenting is developed on this basis to treat and prevent coronary stenosis and restenosis. effective method. After the usual metal stent is implanted into the human body, the direct contact of the metal surface with the blood vessel wall and blood stimulates the human body's ability to reject foreign bodies, resulting in hyperplasia of vascular intimal tissue and smooth muscle cells, resulting in restenosis. In recent years, it has been proposed to prevent restenosis by coating drugs that prevent the proliferation of smooth muscle cells on coronary stents. Due to the single type of drugs coated on the surface of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61L31/16A61L31/12A61F2/88
Inventor 陈伊卫曲刚余少炀
Owner 天津市凯迪亚医疗器械有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap